Evidence map›Paper›PMID 30461380›Full record

ArticleTurkish journal of urology2019

Is active surveillance an appropriate approach to manage prostate cancer patients with Gleason Score 3+3 who met the criteria for active surveillance?

Saleh Ghiasy, Amir Reza Abedi, Afshin Moradi, Seyed Yousef Hosseini, Morteza Fallah Karkan, Ghazal Sadri, Mohammadreza Davari

Abstract read
In one paragraph

Article in Turkish journal of urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Saleh GhiasyInfertility and Reproductive Health Research Center (irhrc), Shahid Beheshti Medical Science University, Tehran, Iran.ORCID http://orcid.org/0000-0002-1835-7441
Amir Reza AbediDepartment of Urology, Shohadae-tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0001-8971-8059
Afshin MoradiDepartment of Pathology, Shohadae-tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0003-1544-0992
Seyed Yousef HosseiniDepartment of Urology, Shahid Modares Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0001-5069-8548
Morteza Fallah KarkanInfertility and Reproductive Health Research Center (irhrc), Shahid Beheshti Medical Science University, Tehran, Iran.ORCID http://orcid.org/0000-0001-8788-2760
Ghazal SadriDepartment of Radiology. Iran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0001-6664-7630
Mohammadreza DavariInfertility and Reproductive Health Research Center (irhrc), Shahid Beheshti Medical Science University, Tehran, Iran.ORCID http://orcid.org/0000-0001-6436-8523

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveProstate cancer is one of the common malignant tumors in men worldwide. Nowadays it seems that Gleason Score 3+3 may not need definite treatment and some of the experts even ignore it as a cancer but we should be aware that in some patients with Gleason Score 3+3 there is a higher risk for harboring higher-grade cancer. We had done this study to evaluate patients with prostate cancer with Gleason Score 3+3 to determine the value of tumor volume in these cases. MATERIAL AND

methodsFrom September 2010 to October 2017, radical prostatectomy was done for 123 sequential patients with localized prostate cancer in two referral centers of Shahid Beheshti Medical University, Tehran, Iran, and 42 cases with Gleason Scores 3+3 which who were candidates for active surveillance were included in the study.

resultsThirty of 42 (71.4%) patients had significant tumor volumes (≥0/5 cm

conclusionWe suggest that some patients with Gleason Score 3+3 have tumor volume >0.5 cm

Identifiers

PMID30461380
PMCPMC6619850

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.